Lineage Cell Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for LCTX

Based on 2 analysts offering 12 month price targets for Lineage Cell Therapeutics Inc.
Min Forecast
Avg Forecast
Max Forecast

Should I buy or sell LCTX stock?

Based on 2 analysts offering ratings for Lineage Cell Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 50%
1 analysts 50%
0 analysts 0%
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LCTX stock forecasts and price targets.

LCTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Bottom 1%
Cantor Fitzgerald
Top 6%
Strong BuyReiterates$6.00+408.47%2023-07-25

1 of 1

LCTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LCTX$1.18$6.50+450.85%Strong Buy
DRTS$2.98$16.00+436.91%Strong Buy
SGMT$9.56$43.33+353.27%Strong Buy

Lineage Cell Therapeutics Stock Forecast FAQ

Is Lineage Cell Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSEMKT: LCTX) stock is to Strong Buy LCTX stock.

Out of 2 analysts, 1 (50%) are recommending LCTX as a Strong Buy, 1 (50%) are recommending LCTX as a Buy, 0 (0%) are recommending LCTX as a Hold, 0 (0%) are recommending LCTX as a Sell, and 0 (0%) are recommending LCTX as a Strong Sell.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.

What is LCTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year LCTX price target, the average LCTX price target is $6.50, with the highest LCTX stock price forecast at $7.00 and the lowest LCTX stock price forecast at $6.00.

On average, Wall Street analysts predict that Lineage Cell Therapeutics's share price could reach $6.50 by Aug 11, 2024. The average Lineage Cell Therapeutics stock price prediction forecasts a potential upside of 450.85% from the current LCTX share price of $1.18.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.